NCT03821857 Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
| NCT ID | NCT03821857 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Mayo Clinic |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 614 participants |
| Start Date | 2019-06-27 |
| Primary Completion | 2030-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 614 participants in total. It began in 2019-06-27 with a primary completion date of 2030-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
Eligibility Criteria
Mayo Clinic Rochester- Inclusion Criteria: * Women who previously participated in this study * Currently aged 60 years and older * More than six months post chemotherapy or major surgery requiring general anesthesia * Willing and able to sign informed consent Exclusion Criteria: * Not able to read and speak English * In hospice * Claustrophobic * If undergoing Tau imaging, cannot have QT Prolongation Mayo Clinic Jacksonville- Inclusion Criteria: * African American Women * Currently aged 60 years and older * More than six months post chemotherapy or major surgery requiring general anesthesia * Willing and able to sign informed consent Exclusion Criteria: * Not able to read and speak English * In hospice * Claustrophobic * If undergoing Tau imaging, cannot have QT Prolongation
Contact & Investigator
Kejal Kantarci, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT03821857 clinical trial?
This trial is open to female participants only, aged 60 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03821857 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT03821857 currently recruiting?
Yes, NCT03821857 is actively recruiting participants. Contact the research team at kendallthomas.june15@mayo.edu for enrollment information.
Where is the NCT03821857 trial being conducted?
This trial is being conducted at Jacksonville, United States, Rochester, United States.
Who is sponsoring the NCT03821857 clinical trial?
NCT03821857 is sponsored by Mayo Clinic. The principal investigator is Kejal Kantarci, MD at Mayo Clinic. The trial plans to enroll 614 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.